* Immunomedics Inc., of Morris Plains, N.J., received two patents.The first, patent No. 5,677,427, describes a new technology for detectingand treating infectious and inflammatory lesions. The patent relates toa chimeric antibody consisting of an antigen-binding part that targetshuman granulocytes combined with a different antibody region that bindsto receptors on mononuclear lymphoid cells. The second, No. 5,686,578,covers drugs targeted to attack chemotherapy resistant cancers or infections.These drugs bind to both the multi-drug resistant proteins (such as P-glycoprotein)and the cancer cells or infectious agents.

* InSite Vision Inc., of Alameda, Calif., and the Universityof Southern California, in Los Angeles, received a notice of allowancefor patent claims covering methods for the diagnosis of glaucoma usingthe trabecular meshwork inducible glucocorticosteroid response (TIGR) gene.The patent covers technologies that contribute to a diagnostic and prognostickit for glaucoma.

* Introgen Therapetuics Inc., of Austin, Texas, reported theUniversity of Texas has received patent No. 5,691,198, covering adenoviralexpression constructs that carry a p16 tumor suppressor gene intendedfor gene-based therapeutics.

* Jenner Biotherapies Inc., of San Ramon, Calif., received apatent covering the liposomal formulation of its vaccine OncoVax-CL. Thecompany was formerly known as Jenner Technologies Inc.

* LXR Biotechnology Inc., of Richmond, Calif., received its thirdpatent in a series describing the company's apoptotic drug screening test.The technology claimed in these patents has led to the discovery and developmentof two apoptosis suppressor compounds, Elirex and Lexirin.

* Matritech Inc., of Newton, Mass., received a notice of allowancefor a patent application covering the use of several breast cancer nuclearmatrix proteins, including NMP66 and NMP43, for identifying and managingpatients with breast cancer. The patent includes the use of NMP66 and NMP43as indicators of breast cancer.

* Medical Science Systems Inc., of Newport Beach, Calif., receiveda patent based on discovery of a gene variation associated with increasedrisk for osteoporosis. The variation occurs in the interleukin-1 receptorantagonist gene.

* Protein Design Labs Inc., of Mountain View, Calif., receivedtwo patents: No. 5,693,762, covering humanized antibodies having preferredhuman frameworks and methods for selecting such human frameworks; and No.5,693,761, covering DNA sequences that encode the humanized antibodiesclaimed by the company's previously issued humanization patents.

* Mitotix Inc., of Cambridge, Mass., received, or holds licensesto, five recent patents centering on regulatory molecules that help controlcritical phases of the cell division cycle: p16, p27, cyclin E and cdc25.They are as follows: No. 5,672,508, covering nucleic acids that encodepeptide fusions; No. 5,691,147, covering a generic assay for screeningcompounds that inhibit the interaction of CDK4 with 24 newly discoveredCDK4 binding proteins; No. 5,688,655, covering recombinant nucleic acidsthat encode human, mouse and mink KIP-1 proteins, vectors, host cells anda method for producing the proteins; No. 5,645,999, covering whole-celland cell-free systems for screening and identifying compounds that modulateor alter cyclin E activity; and No. 5,695,950, covering drug-screeningassays for identification of inhibitors to cdc25A or cdc25B phosphatases.

* Myelos Neurosciences Corp., of San Diego, received a new patent,and holds a license to a second just issued to the University of Californiain San Diego. Both cover therapeutic agents derived from prosaposin andother growth factors under development as therapies for neurological diseases.

No Comments